TFB Advisors LLC Has $821,000 Stake in United Therapeutics Co. (NASDAQ:UTHR)

TFB Advisors LLC lifted its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 19.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,291 shares of the biotechnology company’s stock after buying an additional 376 shares during the period. TFB Advisors LLC’s holdings in United Therapeutics were worth $821,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the last quarter. USA Financial Formulas acquired a new stake in United Therapeutics in the third quarter valued at $33,000. V Square Quantitative Management LLC bought a new position in shares of United Therapeutics in the 2nd quarter valued at about $30,000. Innealta Capital LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth about $33,000. Finally, Values First Advisors Inc. bought a new stake in shares of United Therapeutics in the 3rd quarter valued at about $90,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on UTHR shares. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Bank of America cut their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. Jefferies Financial Group increased their price objective on shares of United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Finally, Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $370.86.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $344.18, for a total value of $1,239,048.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $44,743.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $344.18, for a total transaction of $1,239,048.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 7,802 shares of United Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,422 shares of company stock worth $29,229,828 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $402.57 on Friday. The stock has a market cap of $17.97 billion, a P/E ratio of 17.68, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56. The firm has a 50 day moving average price of $358.27 and a two-hundred day moving average price of $320.94. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $405.98.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the company earned $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. Analysts predict that United Therapeutics Co. will post 25.1 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.